Ok Biotech Co Ltd (4155) - Total Liabilities
Based on the latest financial reports, Ok Biotech Co Ltd (4155) has total liabilities worth NT$1.27 Billion TWD (≈ $40.12 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ok Biotech Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Ok Biotech Co Ltd - Total Liabilities Trend (2009–2025)
This chart illustrates how Ok Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Ok Biotech Co Ltd asset portfolio.
Ok Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Ok Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aniplus Inc
KQ:310200
|
Korea | ₩143.19 Billion |
|
SM Culture & Contents Co. Ltd
KQ:048550
|
Korea | ₩134.83 Billion |
|
Clime Capital Ltd
AU:CAM
|
Australia | AU$43.06 Million |
|
FarmStory Co. Ltd
KQ:027710
|
Korea | ₩648.82 Billion |
|
Nickel 28 Capital Corp
V:NKL
|
Canada | CA$47.43 Million |
|
St. James's Place plc
LSE:STJ
|
UK | GBX244.92 Billion |
|
OptimumBank Holdings, Inc.
NYSE MKT:OPHC
|
USA | $1.14 Billion |
|
Atlantic International Corp. Common Stock
NASDAQ:ATLN
|
USA | $916.79 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Ok Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 4155 net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ok Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ok Biotech Co Ltd (2009–2025)
The table below shows the annual total liabilities of Ok Biotech Co Ltd from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$1.27 Billion ≈ $40.12 Million |
+12.84% |
| 2024-12-31 | NT$1.13 Billion ≈ $35.55 Million |
+67.85% |
| 2023-12-31 | NT$672.26 Million ≈ $21.18 Million |
-44.66% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.27 Million |
+9.47% |
| 2021-12-31 | NT$1.11 Billion ≈ $34.96 Million |
+39.43% |
| 2020-12-31 | NT$795.91 Million ≈ $25.08 Million |
-13.34% |
| 2019-12-31 | NT$918.40 Million ≈ $28.93 Million |
+57.60% |
| 2018-12-31 | NT$582.73 Million ≈ $18.36 Million |
-14.06% |
| 2017-12-31 | NT$678.07 Million ≈ $21.36 Million |
+23.14% |
| 2016-12-31 | NT$550.64 Million ≈ $17.35 Million |
+11.16% |
| 2015-12-31 | NT$495.36 Million ≈ $15.61 Million |
-11.72% |
| 2014-12-31 | NT$561.11 Million ≈ $17.68 Million |
-33.75% |
| 2013-12-31 | NT$847.00 Million ≈ $26.69 Million |
+160.10% |
| 2012-12-31 | NT$325.65 Million ≈ $10.26 Million |
+77.65% |
| 2011-12-31 | NT$183.31 Million ≈ $5.78 Million |
+93.76% |
| 2010-12-31 | NT$94.60 Million ≈ $2.98 Million |
+13.41% |
| 2009-12-31 | NT$83.42 Million ≈ $2.63 Million |
-- |
About Ok Biotech Co Ltd
OK Biotech Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of blood glucose monitoring systems and homecare healthcare devices in Taiwan, the rest of Asia, America, Africa, and Europe. The company offers nebulizers, blood glucose meters, glucometers, blood sugar meters, and blood glucose test strips. It also provides OTC hearing aids, multi-f… Read more